While RPR121056-d3 has not yet been reported as a potential treatment of COVID-19, itraconazole showed an in vitro activity against SARS-CoV-2, possibly by inhibiting oxysterol-binding protein that interferes with intracellular lipid transfer59 and by favoring the cholesterol accumulation in the endosomal membrane preventing the viral transfer into the target cells60. The gene discussed is OSBP; the disease is COVID-19.